[4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone
C24H25N5O3 — CID 141215117
Data last refreshed: (MolForge compound catalog, from PubChem)
About [4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone
[4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone (PubChem CID 141215117) has the molecular formula C24H25N5O3 and a molecular weight of 431.50 g/mol. Its IUPAC name is [4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone.
Molecular Properties
| Compound Name | [4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone |
|---|---|
| PubChem CID | 141215117 |
| Molecular Formula | C24H25N5O3 |
| Molecular Weight | 431.50 g/mol |
| Exact Mass | 431.20 |
| IUPAC Name | [4-(1,2-oxazole-5-carbonyl)piperazin-1-yl]-[3-(5,6,7,8-tetrahydrophthalazin-1-ylmethyl)phenyl]methanone |
| SMILES | O=C(c1cccc(Cc2nncc3c2CCCC3)c1)N1CCN(C(=O)c2ccno2)CC1 |
| InChI | InChI=1S/C24H25N5O3/c30-23(28-10-12-29(13-11-28)24(31)22-8-9-26-32-22)18-6-3-4-17(14-18)15-21-20-7-2-1-5-19(20)16-25-27-21/h3-4,6,8-9,14,16H,1-2,5,7,10-13,15H2 |
| InChIKey | YZMLYYLJRXKCRE-UHFFFAOYSA-N |
| XLogP | 2.53 |
| TPSA | 92.43 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 431.50 |
| LogP ≤ 5 | 2.53 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 141215117 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.